Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Reason given: Kits were not available due to lack of sponsorship
Key facts
- Where
- Ankara, TürkiyeSee the site
Where in Türkiye
- Ankara University, Department of HematologyAnkara, TürkiyeNo longer taking part
Trial details
- Who runs it
- Ugur Arzu Kulu
- Trial code
- NCT06200441
- Record updated
- 29 January 2025
- Original description
The investigators aimed to reveal the relationship between serum markers of pyroptosis, GVHD biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for AML and developed GVHD during follow-up. Secondary outcomes of the study were to demonstrate the role of pyroptosis in the pathophysiology of GVHD and transplantation-associated endothelial injury using serum plasma samples; the efficacy of GVHD biomarkers used to demonstrate organ-specific involvement; and the efficacy of GVHD biomarkers and endothelial injury markers in predicting the development of GVHD, transplantation-associated endothelial injury and non-relapse mortality.Read full original descriptionShow less
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease in AML Patients Undergoing Allogeneic Bone Marrow Transplantation
The investigators aimed to reveal the relationship between serum markers of pyroptosis, GVHD biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for AML and developed GVHD during follow-up. Secondary outcomes of the study were to demonstrate the role of pyroptosis in the pathophysiology of GVHD and transplantation-associated endothelial injury using serum plasma samples; the efficacy of GVHD biomarkers used to demonstrate organ-specific involvement; and the efficacy of GVHD biomarkers and endothelial injury markers in predicting the development of GVHD, transplantation-associated endothelial injury and non-relapse mortality.
Inclusion: 18 years of age or older; Patients with acute myeloid leukemia undergoing allogeneic bone marrow transplantation; Patients followed up by the Department of Hematology, Ankara University Faculty of Medicine Hospitals.
Exclusion: Patients with non-AML transplant indication; Patients under 18 years of age; Patients not followed up by the Department of Hematology, Ankara University Faculty of Medicine Hospitals.